Companion Animal Diagnostic Services Market: as premium instrument installed base expansion and reference laboratory consolidation accelerate recurring diagnostic revenue growth above underlying clinic visit volume, IDEXX's slide-free inVue Dx cellular analyzer and Cancer Dx oncology screening extend the premium instrument portfolio into categories with high pet-owner willingness to pay, so recurring consumable revenue compounds above the visit volume growth rate, and the Mars-SYNLAB Vet European acquisition reshapes the reference laboratory competitive landscape in the region where IDEXX's historical dominance was strongest.

The global companion animal diagnostic services market size was USD 9.84 Billion in 2025 and is expected to register a revenue CAGR of 8.2% during the forecast period. Market revenue growth is driven by factors such as IDEXX Laboratories' premium instrument installed base expansion generating recurring consumable revenue above the underlying veterinary clinic visit volume growth rate, Mars's September 2024 acquisition of SYNLAB Vet reshaping European reference laboratory competitive dynamics, and the IDEXX inVue Dx Cellular Analyzer and Cancer Dx launches extending the premium instrument portfolio into oncology and cellular analysis categories with high pet-owner willingness to pay. The first driving factor is IDEXX's premium instrument installed base expansion generating a structural recurring revenue premium above same-store visit volume growth. IDEXX reported full-year 2024 revenue of USD 3,898 Million, an increase of 6% as reported and organically, with CAG Diagnostics recurring revenue organic growth of 7% in the fourth quarter reflecting double-digit IDEXX VetLab consumable gains and solid reference laboratory and consulting services growth, maintaining a consistent premium to US same-store clinical visit growth throughout 2024. The second driving factor is the launch of IDEXX inVue Dx and Cancer Dx extending the premium instrument portfolio into oncology screening. IDEXX began shipping the inVue Dx Cellular Analyzer in Q4 2024 with nearly 700 pre-orders, and confirmed plans to make Cancer Dx canine lymphoma screening available in the United States and Canada by late March 2025, entering categories where pet-owner willingness to pay premium prices is highest because the emotional stakes of cancer diagnosis are most acute. The third driving factor is Mars's acquisition of SYNLAB Vet expanding European reference laboratory capacity alongside Antech's established North American infrastructure. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way each premium instrument placement generates a multi-year recurring consumable revenue stream that compounds as the installed base grows independently of individual clinic visit volume fluctuations, which allows IDEXX's diagnostic revenue to sustain growth above the underlying veterinary sector even as post-pandemic clinic visit volume normalises. Once a veterinary clinic installs an IDEXX VetLab premium instrument under a multi-year equipment placement contract, each clinical test run on that instrument generates consumable revenue per test regardless of whether the total visit count for that clinic is growing, flat, or modestly declining, so the per-clinic diagnostic revenue base compounds as the testing menu per visit expands and new instruments are placed alongside existing ones. As a result, demand and revenue share are concentrating around IDEXX and Mars/Antech, whose combined premium instrument installed base and reference laboratory network depth creates consumable and service revenue streams that smaller point-of-care instrument companies and independent reference laboratories cannot match at scale, and the forecast tilts toward these integrated platform incumbents rather than point-of-care single-analyte device manufacturers. For instance, in April 2024, VolitionRx launched its Nu.Q Vet Cancer Test through Antech Diagnostics in US and European veterinary clinics, delivering six-minute in-clinic canine cancer screening on the Element i+ Analyzer, adding one of more than a dozen oncology screening test initiatives that IDEXX and Antech together launched in the 2024 to 2025 period and confirming the competitive race to extend diagnostic revenue into premium oncology screening categories. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is IDEXX's strategic extension of its premium instrument portfolio into the oncology screening and slide-free cellular analysis categories, which command higher per-test consumable revenue per patient visit than the established clinical chemistry and hematology instrument categories that anchor IDEXX's existing installed base. Premium instrument extension into new testing categories works as a demand driver because each new instrument category placed at a veterinary clinic adds a new revenue layer on top of the existing consumable base without replacing any existing instrument revenue, so the per-clinic diagnostic revenue compounds as the number of distinct premium instrument categories per practice location increases. IDEXX began shipping its inVue Dx Cellular Analyzer, described by CEO Jay Mazelsky as a transformational slide-free cellular analyzer, during the fourth quarter of 2024, with the company confirming nearly 700 pre-orders of the platform ahead of shipment and noting that customers especially value IDEXX technology solutions like inVue Dx that provide meaningful clinical insights while giving time back to busy veterinary practice staff. IDEXX confirmed in its February 2025 full-year results that plans were on track to make IDEXX Cancer Dx screening for canine lymphoma available in the United States and Canada by late March 2025, extending the diagnostic portfolio into oncology screening that previously required specialist reference laboratory cytopathology submission and follow-up appointment timing. The effect on the market is a compounding per-practice revenue uplift at every clinic that adds inVue Dx or Cancer Dx to its existing IDEXX VetLab instrument suite, creating a structural growth rate above same-store visit volume growth as the premium instrument footprint per practice location deepens. These are some of the key factors driving revenue growth of the market.

The second driver is Mars's systematic vertical integration of companion animal diagnostic services through the September 2024 acquisition of SYNLAB Vet, which expands the company's European veterinary reference laboratory, advanced imaging, and telemedicine capabilities alongside its existing Antech Diagnostics, Banfield, BluePearl, VCA Animal Hospitals, SOUND, and AniCura portfolio. Reference laboratory consolidation through acquisition works as a demand driver because it converts previously independent regional veterinary reference laboratory volumes onto the Mars/Antech platform at the point of acquisition, generating immediate top-line revenue gains without requiring organic new client acquisition, and then creates cross-selling opportunities for Mars's broader companion animal health platform across the acquired customer base. Mars acquired SYNLAB Vet in September 2024, expanding the company's veterinary diagnostics capabilities across Europe with advanced diagnostics, imaging, and telemedicine solutions, representing the most consequential European market consolidation event in companion animal diagnostics during the period and directly challenging IDEXX's historical commanding European reference laboratory market position. In April 2024, VolitionRx launched its Nu.Q Vet Cancer Test in US and European veterinary clinics through Antech, enabling rapid in-clinic canine cancer screening on the Element i+ Analyzer with results delivered in approximately six minutes, demonstrating Mars's parallel strategy of partnership-based test menu expansion alongside direct laboratory capacity acquisition. The effect on the market is an accelerated two-platform competitive consolidation at global scale, with IDEXX and Mars/Antech together accounting for the substantial majority of companion animal diagnostic services revenue through their combined instrument, reference laboratory, and owned clinic network assets. These are some of the key factors driving revenue growth of the market.

"The 900 basis point premium IDEXX maintained between its US CAG Diagnostics recurring revenue growth and same-store clinical visit growth is the number that explains why IDEXX keeps outgrowing the sector even as underlying clinic visit volume normalises post-pandemic. That premium comes from three execution levers: instrument placements expanding the testing menu per visit, net price realisation, and new business gains from clinics switching vendors. The inVue Dx launch with 700 pre-orders before shipping even began tells you IDEXX has genuine pricing power and customer trust built over years of reliable platform performance."

Clarivant Analyst Intelligence, Q1 2026

The third driver is the structural growth of companion animal ownership and the increasing medicalisation of veterinary care in Asia Pacific and European markets, which expands the total addressable diagnostic services market through population and behaviour-driven volume growth that benefits all veterinary diagnostic services providers simultaneously. Ownership growth and medicalisation work as structural demand drivers because they expand the base of companion animals receiving annual veterinary care and the average number of diagnostic tests per visit as pet owners increasingly expect the same multi-modality diagnostic standard for their pets that they receive in their own healthcare, so the per-animal diagnostic services revenue compounds as both the pet population and the testing intensity per visit increase. IDEXX confirmed double-digit international CAG Diagnostics recurring revenue growth throughout 2024, and Mars's AniCura network in continental Europe and SYNLAB Vet acquisition confirm the expansion of premium veterinary diagnostic services infrastructure beyond the established North American clinical base. China, Japan, and Australia represent the three largest national companion animal diagnostic services markets within Asia Pacific, with China's rapidly growing urban pet ownership base representing a structural long-term demand tailwind as veterinary clinic density and care medicalisation rates continue to converge toward North American and Northern European standards. The effect on the market is a geographic diversification of the diagnostic services revenue base away from North American same-store visit growth and toward structural population and medicalisation growth in Asia Pacific and European markets over the forecast period. These are some of the key factors driving revenue growth of the market.

However, the companion animal diagnostic services market faces adoption constraints from veterinary clinic visit volume normalisation following the post-pandemic pet ownership surge, and from litigation-related cost exposure and pricing sensitivity that accompany that normalisation. The visit volume normalisation constraint is the most immediate market growth headwind, since IDEXX's 2024 results showed that while CAG Diagnostics recurring revenue maintained a growth premium to same-store visit volume, the underlying visit volume growth itself has moderated from the double-digit pandemic-era peaks that were a structural tailwind for the entire companion animal healthcare sector between 2020 and 2022, reducing the contribution of new patient volume to diagnostic services revenue growth and placing greater weight on menu expansion and price realisation to sustain the overall growth rate. IDEXX's discrete litigation expense accrual of USD 0.56 per share in Q2 2024 is a second constraint, illustrating the ongoing legal and regulatory cost exposure that companion animal diagnostic services companies face as the industry scales, attracts increased commercial and intellectual property litigation scrutiny, and must balance investment in legal defence with investment in product development and commercial execution, creating earnings volatility that is structurally outside operational management's control. Diagnostic service pricing sensitivity is a third constraint, since veterinary clinic customers face their own margin pressure from rising veterinary staff costs, facility expenses, and equipment maintenance costs, so diagnostic services companies that attempt to sustain net price realisation above clinic cost inflation rates face customer attrition risk to lower-cost alternative providers, particularly in the reference laboratory testing segment where IDEXX, Mars/Antech, and independent regional reference laboratories compete for the same clinic referral volumes on a price and turnaround time basis. These factors substantially limit companion animal diagnostic services market growth over the forecast period.

Based on service type, the global companion animal diagnostic services market is segmented into in-clinic point-of-care testing, reference laboratory testing, and telemedicine and remote consultation services. In-clinic point-of-care testing holds the largest revenue share, because the standard veterinary clinical practice preference for same-visit diagnostic results that enable immediate treatment decisions without patient recall appointments has driven the majority of companion animal diagnostic revenue onto IDEXX VetLab and equivalent in-clinic instrument platforms at veterinary clinics globally, and the premium instrument installed base expansion model generates recurring consumable revenue that grows with the installed base even as individual clinic visit volume growth moderates. Reference laboratory testing is expected to register the fastest revenue growth rate in the global companion animal diagnostic services market over the forecast period, driven by Mars's September 2024 SYNLAB Vet acquisition expanding European reference laboratory capacity and the expansion of specialist cytopathology and oncology testing referral volumes from in-clinic practices that require specialist pathologist interpretation, with IDEXX and Antech reference laboratory networks each expanding their oncology and advanced testing menus.

Clinical chemistry test category is expected to account for a significantly large revenue share in the global companion animal diagnostic services market during the forecast period

Based on test category, the global companion animal diagnostic services market is segmented into clinical chemistry, hematology, immunoassay and infectious disease, and cytology and histopathology. Clinical chemistry holds the largest revenue share through the established IDEXX VetLab chemistry analyzer installed base at veterinary clinics processing routine biochemistry panels for wellness examinations, pre-anaesthetic screening, and chronic disease management monitoring across canine and feline patients. Hematology represents the second-established test category, sharing premium instrument platforms with clinical chemistry at most veterinary clinic in-clinic testing installations. Cytology and histopathology is expected to register a rapid revenue growth rate in the global companion animal diagnostic services market over the forecast period, driven by IDEXX inVue Dx slide-free cellular analyzer adoption extending cytological analysis into the in-clinic point-of-care setting and the IDEXX Cancer Dx and Antech Nu.Q Vet Cancer Test launches expanding oncology-focused cytological and molecular testing availability.

Based on animal type, the global companion animal diagnostic services market is segmented into canine and feline testing. Canine testing holds the largest revenue share, reflecting both the larger global population of pet dogs relative to cats in most major markets and the broader range of diagnostic testing typically performed across canine wellness, chronic disease management, and oncology screening, including the cancer-specific testing products that IDEXX and Antech have both prioritised with canine-specific initial indications for inVue Dx, Cancer Dx, and Nu.Q Vet Cancer Test. Feline testing is expected to register a rapid revenue growth rate in the global companion animal diagnostic services market over the forecast period, driven by the increasing prevalence of feline chronic kidney disease and hyperthyroidism testing as cat owners increasingly pursue veterinary diagnostic and wellness services at rates approaching those historically associated with dog ownership, and by IDEXX's expanding feline-specific assay menu on its premium instrument platforms.

Based on regional analysis, the companion animal diagnostic services market in North America accounted for largest revenue share in 2025. The United States leads because IDEXX Laboratories is headquartered in Westbrook, Maine, and Mars's Antech Diagnostics, Banfield, BluePearl, VCA Animal Hospitals, and SOUND networks represent the two largest global companion animal diagnostic services platforms with the deepest commercial infrastructure and veterinary clinic customer relationships in the United States. IDEXX confirmed that US CAG Diagnostics recurring revenue growth maintained a consistent premium to US same-store clinical visit growth throughout 2024, with the 900 basis point growth premium between the two metrics reflecting the structural depth of the North American veterinary diagnostics customer base across premium instrument placement, net price realisation, and new business gains that sustain revenue growth above the moderated underlying visit volume trend. The concentration of IDEXX and Mars/Antech's commercial and laboratory infrastructure in North America also means that new product launches including inVue Dx, Cancer Dx, and Nu.Q Vet Cancer Test were first commercially available in the United States before international market rollout.

The market in Europe is expected to register a rapid revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national companion animal diagnostic services markets within Europe. Mars's September 2024 acquisition of SYNLAB Vet specifically expanded the company's veterinary diagnostics capabilities across Europe with advanced diagnostics, imaging, and telemedicine solutions, representing the most consequential European companion animal diagnostic services market consolidation event in the period and directly challenging IDEXX's historical commanding European reference laboratory market share. The ongoing Iran-US sanctions and associated Strait of Hormuz maritime disruption through 2026 affect specialty reagent and antibody component supply chains for European veterinary diagnostic reagent manufacturers, adding import cost pressure to European diagnostic test pricing.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and Australia represent the three largest national companion animal diagnostic services markets within the region, driven by rising companion animal ownership rates and expanding veterinary clinic infrastructure investment across urban centres in China and broader Asia Pacific markets. IDEXX confirmed double-digit international CAG Diagnostics recurring revenue growth throughout 2024, confirming Asia Pacific as a primary contributor to international growth, and the rapidly expanding urban pet ownership base in China leaves substantially more room for veterinary care medicalisation growth than in North America or Western Europe where IDEXX's installed base penetration is already advanced.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national companion animal diagnostic services markets within the region, supported by expanding private veterinary clinic infrastructure and rising pet healthcare expenditure at urban veterinary practice networks. The Iran-US sanctions and Strait of Hormuz disruption have maintained elevated import costs for veterinary diagnostic reagents and instrument consumables entering Brazilian and Mexican distribution networks through 2026, slowing premium instrument placement timelines and reference laboratory consumable cost efficiency at regional diagnostic services providers beyond the primary commercial centres in Sao Paulo, Mexico City, and Guadalajara.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the United Arab Emirates represent the primary commercial companion animal diagnostic services markets within the GCC, with growing companion animal ownership and veterinary clinic infrastructure investment supporting diagnostic services demand at private veterinary hospitals serving the expatriate and emerging domestic pet-owning populations across the region. South Africa is the most established market on the African continent for companion animal diagnostic services, with Onderstepoort Veterinary Academic Hospital and private veterinary clinic networks in Johannesburg and Cape Town representing the primary diagnostic services deployment sites, while the Gulf states are still building the veterinary specialist physician capacity and clinical infrastructure that would sustain routine premium diagnostic services demand at IDEXX and Antech reference laboratory volumes.